Form 4: Biogen CEO's RSU Vesting and Tax-Related Stock Sale
Insider Transaction Report
Biogen's President and CEO, Christopher Viehbacher, reported the vesting of 7,040 Restricted Stock Units and a subsequent sale of 3,404 shares for tax obligations.
Summary
- Christopher Viehbacher, President and CEO, and Director of Biogen Inc. (BIIB), reported changes in his beneficial ownership of common stock.
- On December 1, 2025, 7,040 Restricted Stock Units (RSUs) vested, representing the right to receive an equal number of common shares.
- These RSUs were granted on December 1, 2022, and vested on their third anniversary.
- Following the vesting, 7,040 shares of common stock were acquired at a price of $0 per share.
- Concurrently, 3,404 shares of common stock were disposed of at a price of $177.78 per share to cover tax liabilities associated with the RSU vesting.
- My beneficial ownership of common stock decreased from 19,847 shares to 16,443 shares after these transactions.
Sentiment
Score: 5
Explanation: The filing reports a routine insider transaction involving the vesting of Restricted Stock Units and a subsequent tax-related sale, which is a neutral event in terms of company performance or strategic direction.
Positives
- The vesting of 7,040 Restricted Stock Units indicates the successful completion of a long-term incentive compensation milestone for the CEO.
Negatives
- A portion of the vested shares (3,404 shares) was sold to cover tax obligations, resulting in a net reduction of 3,404 shares in direct beneficial ownership.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This is a routine insider transaction filing (Form 4) detailing executive compensation events, which does not typically provide insights into broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: The transaction represents a routine compensation event for the CEO and a minor change in insider ownership, unlikely to have a significant direct impact on shareholder value.
- Employees: No direct impact on employees is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 12/01/2022 | Grant date of the Restricted Stock Units (RSUs). |
| 12/01/2025 | Vesting date of the Restricted Stock Units and transaction date for stock acquisition and disposition. |
| 12/03/2025 | Date the Form 4 filing was signed. |
Keywords
Biogen, BIIB, Christopher Viehbacher, Form 4, Insider Transaction, Restricted Stock Unit, RSU Vesting, Stock Sale, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.